Product logins

Find logins to all Clarivate products below.


Blog: Biopharma

Here you will find relevant articles and insight into all Clarivate related products and news.

The competitive signals hiding in plain sight for biopharma The competitive signals hiding in plain sight for biopharma
Blog May 8, 2026
The competitive signals hiding in plain sight for biopharma
Biopharma Business Development Clinical trials
Five lessons learned deploying agentic AI in the life sciences Five lessons learned deploying agentic AI in the life sciences
Blog April 30, 2026
Five lessons learned deploying agentic AI in the life sciences
AI
Target selection and safety assessment: Navigating early decisions that shape drug development Target selection and safety assessment: Navigating early decisions that shape drug development
Blog March 27, 2026
Target selection and safety assessment: Navigating early decisions that shape drug development
Development Pharma Regulatory
Drugs to Watch 2026 Q&A: Lilly’s next-generation weight loss drugs Drugs to Watch 2026 Q&A: Lilly’s next-generation weight loss drugs
Blog March 26, 2026
Drugs to Watch 2026 Q&A: Lilly’s next-generation weight loss drugs
GLP-1 Metabolic
Why longevity might be biopharma's next big thing: The science and business converge Why longevity might be biopharma's next big thing: The science and business converge
Blog March 2, 2026
Why longevity might be biopharma's next big thing: The science and business converge
Gerontology
Why ease of administration in new drugs sometimes draws a yawn from payers Why ease of administration in new drugs sometimes draws a yawn from payers
Blog February 26, 2026
Why ease of administration in new drugs sometimes draws a yawn from payers
Biopharma Biotech Clinical trials
The path forward: What comes after a CRL? The path forward: What comes after a CRL?
Blog February 24, 2026
The path forward: What comes after a CRL?
Biopharma Biotech Clinical trials
Relacorilant:  when evidence meets the established evidence bar Relacorilant:  when evidence meets the established evidence bar
Blog February 24, 2026
Relacorilant: when evidence meets the established evidence bar
FDA Regulatory Safety

Biopharma

COVID-19: Fighting a global pandemic with innovation COVID-19: Fighting a global pandemic with innovation
Blog October 14, 2021
COVID-19: Fighting a global pandemic with innovation
Pharmacy benefit reform in Medicaid addresses drug transparency Pharmacy benefit reform in Medicaid addresses drug transparency
Blog October 8, 2021
Pharmacy benefit reform in Medicaid addresses drug transparency
Top oncology breakthroughs shared at ESMO 2021 Top oncology breakthroughs shared at ESMO 2021
Blog October 7, 2021
Top oncology breakthroughs shared at ESMO 2021
Healthcare consolidation paves way for care delivery changes Healthcare consolidation paves way for care delivery changes
Blog September 15, 2021
Healthcare consolidation paves way for care delivery changes
Three key trends in regulatory approvals of new medicines Three key trends in regulatory approvals of new medicines
Blog July 22, 2021
Three key trends in regulatory approvals of new medicines
Home healthcare: The house call makes a comeback Home healthcare: The house call makes a comeback
Blog July 22, 2021
Home healthcare: The house call makes a comeback
Open Access Journal Database on Dialog: Publicly Available Content Open Access Journal Database on Dialog: Publicly Available Content
Blog June 28, 2021
Open Access Journal Database on Dialog: Publicly Available Content
Paradigm-changing primary Phase III data for malignant melanoma: What to expect from Relatlimab in combination with Opdivo Paradigm-changing primary Phase III data for malignant melanoma: What to expect from Relatlimab in combination with Opdivo
Blog June 23, 2021
Paradigm-changing primary Phase III data for malignant melanoma: What to expect from Relatlimab in combination with Opdivo
KEYNOTE-564 paves future role for immunotherapy in adjuvant renal cell carcinoma KEYNOTE-564 paves future role for immunotherapy in adjuvant renal cell carcinoma
Blog June 21, 2021
KEYNOTE-564 paves future role for immunotherapy in adjuvant renal cell carcinoma
The evolution of the asset-centric approach in biotech venture capital The evolution of the asset-centric approach in biotech venture capital
Blog June 18, 2021
The evolution of the asset-centric approach in biotech venture capital